Beta Bionics, Inc. Common Stock (BBNX)

• Market cap: $1B
• 1 day: -0.86%
• 5 days: -8.55%
• 1 month: 33.78%
• 3 months: 26.66%
• 6 months: 39.01%
• Year to date: -2.29%
• 1 year: -2.29%
• 5 years: -2.29%
• 10 years: -2.29%
• Sector: Healthcare
• Industry: Medical Devices

About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

Employees: 392

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

108% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 13

30% more capital invested

Capital invested by funds: $508M [Q1] → $659M (+$151M) [Q2]

24% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 29

13% more funds holding

Funds holding: 102 [Q1] → 115 (+13) [Q2]

7.24% more ownership

Funds ownership: 96.2% [Q1] → 103.44% (+7.24%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17
• Avg. target: $19
• High target: $21

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Truist Securities Richard Newitter	$21	Buy Maintained	30 Jul 2025
Baird Jeff Johnson	$17	Neutral Maintained	30 Jul 2025